U.S. markets open in 6 hours 18 minutes
  • S&P Futures

    4,219.00
    +9.25 (+0.22%)
     
  • Dow Futures

    33,368.00
    +64.00 (+0.19%)
     
  • Nasdaq Futures

    13,349.25
    +38.00 (+0.29%)
     
  • Russell 2000 Futures

    1,982.60
    +6.30 (+0.32%)
     
  • Crude Oil

    94.09
    -0.25 (-0.26%)
     
  • Gold

    1,808.40
    +1.20 (+0.07%)
     
  • Silver

    20.38
    +0.03 (+0.13%)
     
  • EUR/USD

    1.0317
    -0.0009 (-0.08%)
     
  • 10-Yr Bond

    2.8880
    0.0000 (0.00%)
     
  • Vix

    20.20
    +0.46 (+2.33%)
     
  • GBP/USD

    1.2203
    +0.0001 (+0.01%)
     
  • USD/JPY

    133.2850
    +0.2860 (+0.22%)
     
  • BTC-USD

    23,960.44
    -592.49 (-2.41%)
     
  • CMC Crypto 200

    569.01
    -5.74 (-1.00%)
     
  • FTSE 100

    7,465.91
    0.00 (0.00%)
     
  • Nikkei 225

    28,546.98
    +727.65 (+2.62%)
     

ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2022 Operating Results

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

WALTHAM, Mass., July 14, 2022--(BUSINESS WIRE)--ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, July 29, 2022 to discuss its second quarter 2022 operating results. Management will also provide a brief update on the business.

CONFERENCE CALL INFORMATION

To access the live call by phone, please register here. A dial-in and unique PIN will be provided to join the call. The call may also be accessed through the Investors and Media section of the Company’s website, www.immunogen.com. Following the call, a replay will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220714005101/en/

Contacts

INVESTOR RELATIONS CONTACT
ImmunoGen
Anabel Chan
781-895-0600
anabel.chan@immunogen.com

MEDIA CONTACTS
ImmunoGen
Courtney O’Konek
781-895-0600
courtney.okonek@immunogen.com

OR

FTI Consulting
Robert Stanislaro
212-850-5657
robert.stanislaro@fticonsulting.com